109208-40-4Relevant articles and documents
Formal synthesis of a 2- and 8-functionalized 1,4,7-trioxa-10-azaspiro[5.5]undecane
Lemaire,Posada,Gourcy,Jeminet
, p. 627 - 629 (1995)
(E,E)-(2R,6S,8R )-(+)-N-Benzoyl-2,8-dihydroxymethyl-1,4,7-trioxa-10-azaspiro[5.5]undec ane was synthesised in seven steps from (S)-isopropylideneglycerol as chiral precursor. The final cyclodehydration reaction was carried out on a dihydroxyamidoketone intermediate.
Third-generation immucillins: Syntheses and bioactivities of acyclic immucillin inhibitors of human purine nucleoside phosphorylase
Clinch, Keith,Evans, Gary B.,Frohlich, Richard F. G.,Furneaux, Richard H.,Kelly, Peter M.,Legentil, Laurent,Murkin, Andrew S.,Li, Lei,Schramm, Vern L.,Tyler, Peter C.,Woolhouse, Anthony D.
body text, p. 1126 - 1143 (2010/02/16)
ImmH (1) and DADMe-ImmH (2) are potent inhibitors of human purine nucleoside phoshorylase (PNP), developed by us and currently in clinical trials for the treatment of a variety of T-cell related diseases. Compounds 1 and 2 were used as templates for the design and synthesis of a series of acyclic immucillin analogues (8-38) in order to identify simplified alternatives to 1 and 2. SerMe-ImmG (8) and DATMe- ImmG (9) displayed the lowest inhibition constants of 2.1 and 3.4 pM, respectively, vs PNP. It was postulated that the flexible natures of 8 and 9 enabled them to adopt conformations resembling those of 1 and 2 within the active site of PNP and that the positioning of two hydroxyl groups was critical for picomolar activity. SerMe-ImmH (10, K d = 5.2 pM) was shown to be orally available in mice with a long biological residence time on blood PNP.
ACYCLIC AMINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE
-
Page/Page column 22, (2008/06/13)
The present invention relates to compounds of the general formula (I) which are inhibitors of 5'-methylthioadenosine phosphorylase or 5'-methylthioadenosine nucleosidase. The invention also relates to the use of these compounds in the treatment of diseases or conditions in which it is desirable to inhibit 5'-methylthioadenosine phosphorylase or 5'-methylthioadenosine nucleosidase including cancer, and to pharmaceutical compositions containing the compounds.